查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1974018

雙特異性抗體市場分析及預測（至2035年）：按類型、產品、技術、成分、應用、最終用戶、製程、部署、功能及階段分類

Bispecific Antibodies Market Analysis and Forecast to 2035: Type, Product, Technology, Component, Application, End User, Process, Deployment, Functionality, Stage
出版日期: | 出版商: Global Insight Services | 英文 376 Pages | 商品交期: 3-5個工作天內

價格
簡介目錄

雙特異性抗體市場預計將從2024年的123億美元成長到2034年的256億美元，複合年成長率約為7.6%。雙特異性抗體市場包括旨在結合兩種不同抗原的治療藥物，可增強標靶治療在腫瘤學、免疫學和感染疾病的療效。這些創新分子能夠提高特異性並減少脫靶效應。基因工程的進步和癌症發生率的上升是推動市場成長的主要因素，促進了新型治療方法的開發以及生物製藥公司之間的策略聯盟。

受標靶治療和免疫腫瘤學進展的推動，雙特異性抗體市場正經歷強勁成長。腫瘤領域引領市場，其中骨髓惡性腫瘤因其巨大的治療潛力而佔主導地位。固態腫瘤領域緊隨其後，反映出研究投入和臨床試驗的增加。在各細分領域中，基於CD3的雙特異性抗體表現最佳，這得益於其有效活化T細胞的能力。 CD20/CD3雙特異性抗體因其在B細胞惡性腫瘤的療效，預計未來將備受關注。自體免疫疾病領域也呈現成長勢頭，雙特異性抗體為該領域提供了新的治療選擇。在該領域，針對TNF-α和IL-6的抗體正成為極具潛力的候選藥物。抗體工程和雙特異性形式（例如雙親和性重定向）的技術進步正在提高治療效果和安全性。生物製藥公司之間的策略聯盟和夥伴關係正在加速開發平臺，促進創新，並拓展市場格局。對個人化醫療的需求進一步推動了市場成長。

市場區隔
類型 T細胞結合抗體、NK細胞結合抗體、抗體藥物複合體（ADC）、親和性標靶化抗體、雙功能抗體、三功能抗體
產品 治療性抗體、診斷性抗體、研究性抗體、客製化抗體
科技 融合瘤技術、噬菌體展示技術、基因轉殖小鼠技術、單B細胞技術
成分 輕鏈、重鏈、Fc區、抗原結合位點
目的 腫瘤學、自體免疫疾病、感染疾病、心血管疾病、神經系統疾病
最終用戶 製藥公司、生技公司、研究機構、受託研究機構
過程 藥物發現、開發、生產、品管和監管核准。
發展 內部開發、外包、混合模式
功能 標靶結合、免疫調節、訊號傳導
步 臨床前研究、臨床試驗、商業化

市場概況：

由於創新定價策略和突破性產品的推出，雙特異性抗體市場正經歷市場佔有率的動態重組。各公司正專注於策略性產品發布，以滿足尚未滿足的市場需求並增強自身競爭優勢。市場格局的特點是擁有強大的產品平臺，專注於新的治療領域，這種策略方針正在推動競爭格局的形成。定價在市場滲透和消費者接受度方面發揮著至關重要的作用。雙特異性抗體市場的競爭異常激烈，各大製藥巨頭都在爭奪主導。基準研究表明，法規結構對市場趨勢有顯著的影響。北美和歐洲處於領先地位，嚴格的監管標準塑造市場動態。與此同時，亞太地區正經歷投資激增和監管放鬆，營造出有利於成長的環境。這些因素的相互作用為尋求把握新成長機會的相關人員創造了一個複雜而又充滿希望的局面。

主要趨勢和促進因素：

在生物技術進步和癌症發病率上升的推動下，雙特異性抗體市場正經歷強勁成長。這些抗體因其標靶治療的優勢而備受青睞，它們在提高療效的同時，也能最大限度地減少副作用。關鍵趨勢包括新型雙特異性結構的開發、特異性和功能的提升，以及腫瘤治療應用範圍的擴展。製藥公司正大力投資研發，以創造創新的雙特異性抗體平台。這些投資正在加速產品平臺的開發，並加快監管核准。策略聯盟和夥伴關係的增加正在增強技術能力並擴大市場。此外，對個人化醫療的日益關注也為雙特異性抗體滿足未被滿足的醫療需求創造了機會。新興市場由於醫療保健支出的成長和基礎設施的進步，蘊藏著巨大的潛力。對先進生物製藥日益成長的需求為市場相關人員帶來了盈利的利潤。隨著人們對雙特異性抗體的認知不斷提高，在技術創新和策略性產業合作的推動下，預計該市場將實現持續成長。

壓制與挑戰：

雙特異性抗體市場面臨許多重大限制與挑戰。其中一項主要挑戰是其複雜的生產流程，這需要專門的設施和專業技術，導致生產成本增加。這種複雜性會阻礙規模化生產，並限制其滿足不斷成長的需求的能力。監管障礙也是一項重大挑戰。雙特異性抗體嚴格的核准流程會延遲其進入市場，並增加研發成本。企業必須應對因地區而異的複雜法規環境，這使得國際擴張舉步維艱。此外，該市場還面臨來自傳統單株抗體和其他新興治療方法的激烈競爭。這些替代療法通常具有成熟的療效和安全性，使得雙特異性抗體難以立足。另外，缺乏熟悉雙特異性抗體療法開發和管理的專業人才也是一項挑戰。人才短缺會減緩創新，阻礙該領域的發展。最後，報銷問題也是一大障礙。雙特異性抗體的高成本使得企業難以獲得保險公司的報銷，這可能會限制病患的用藥機會和市場成長。

目錄

第1章摘要整理

第2章 市場亮點

第3章 市場動態

  • 宏觀經濟分析
  • 市場趨勢
  • 市場促進因素
  • 市場機遇
  • 市場限制因素
  • 複合年均成長率：成長分析
  • 影響分析
  • 新興市場
  • 技術藍圖
  • 戰略框架

第4章：細分市場分析

  • 市場規模及預測：依類型
    • T細胞銜接器
    • NK細胞銜接器
    • 抗體藥物複合體
    • 親和性重定向抗體
    • 雙功能抗體
    • 三功能抗體
  • 市場規模及預測：依產品分類
    • 治療性抗體
    • 診斷抗體
    • 研究抗體
    • 客製化抗體
  • 市場規模及預測：依技術分類
    • 融合瘤技術
    • 噬菌體展示技術
    • 基因轉殖小鼠技術
    • 單B細胞技術
  • 市場規模及預測：依組件分類
    • 輕鏈
    • 重鏈
    • 鋒區
    • 抗原結合位點
  • 市場規模及預測：依應用領域分類
    • 腫瘤學
    • 自體免疫疾病
    • 感染疾病
    • 心血管疾病
    • 神經系統疾病
  • 市場規模及預測：依最終用戶分類
    • 製藥公司
    • 生技公司
    • 研究機構
    • 受託研究機構
  • 市場規模及預測：依製程分類
    • 藥物發現
    • 發展
    • 製造業
    • 品管
    • 監管部門核准
  • 市場規模及預測：依市場細分
    • 內部開發
    • 外包
    • 混合
  • 市場規模及預測：依功能分類
    • 標靶結合
    • 免疫調節
    • 訊號傳導
  • 市場規模及預測：依階段分類
    • 臨床前階段
    • 臨床試驗
    • 市售產品

第5章 區域分析

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 拉丁美洲
    • 巴西
    • 阿根廷
    • 其他拉丁美洲
  • 亞太地區
    • 中國
    • 印度
    • 韓國
    • 日本
    • 澳洲
    • 台灣
    • 亞太其他地區
  • 歐洲
    • 德國
    • 法國
    • 英國
    • 西班牙
    • 義大利
    • 其他歐洲國家
  • 中東和非洲
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非
    • 撒哈拉以南非洲
    • 其他中東和非洲地區

第6章 市場策略

  • 供需差距分析
  • 貿易和物流限制
  • 價格、成本和利潤率趨勢
  • 市場滲透率
  • 消費者分析
  • 監管概述

第7章 競爭訊息

  • 市場定位
  • 市場占有率
  • 競爭基準
  • 主要企業的策略

第8章：公司簡介

  • Genmab
  • MacroGenics
  • Crescendo Biologics
  • F-star Therapeutics
  • Xencor
  • Zymeworks
  • Affimed
  • Harpoon Therapeutics
  • Immunocore
  • AbCellera
  • Regeneron Pharmaceuticals
  • Pieris Pharmaceuticals
  • Adimab
  • Ichnos Sciences
  • Sorrento Therapeutics

第9章 關於我們

簡介目錄
Product Code: GIS33684

Bispecific Antibodies Market is anticipated to expand from $12.3 billion in 2024 to $25.6 billion by 2034, growing at a CAGR of approximately 7.6%. The Bispecific Antibodies Market encompasses therapeutics engineered to bind two distinct antigens, enhancing targeted treatment efficacy in oncology, immunology, and infectious diseases. These innovative molecules offer improved specificity and reduced off-target effects. Market growth is propelled by advancements in genetic engineering and increasing cancer prevalence, fostering novel therapeutic development and strategic collaborations among biopharmaceutical entities.

The Bispecific Antibodies Market is experiencing robust growth, propelled by advancements in targeted therapies and immuno-oncology. The oncology segment dominates, with hematologic malignancies leading due to their high therapeutic potential. Solid tumors follow closely, reflecting increasing research investments and clinical trials. In terms of sub-segments, the CD3-based bispecific antibodies are top performers, leveraging their ability to engage T-cells effectively. CD20/CD3 bispecifics are expected to witness significant traction, driven by their efficacy in B-cell malignancies. The autoimmune disorders segment is also gaining momentum, with bispecific antibodies offering novel treatment avenues. Within this, the TNF-alpha and IL-6 targeting antibodies are emerging as promising candidates. Technological advancements in antibody engineering and bispecific formats, such as dual-affinity re-targeting, are enhancing therapeutic efficacy and safety profiles. Strategic collaborations and partnerships among biopharmaceutical companies are accelerating the development pipeline, fostering innovation and expanding the market landscape. The demand for personalized medicine further bolsters market growth.

Market Segmentation
TypeT-cell Engagers, NK-cell Engagers, Antibody-Drug Conjugates, Dual-Affinity Re-Targeting Antibodies, Bifunctional Antibodies, Trifunctional Antibodies
ProductTherapeutic Antibodies, Diagnostic Antibodies, Research Antibodies, Custom Antibodies
TechnologyHybridoma Technology, Phage Display Technology, Transgenic Mouse Technology, Single B Cell Technology
ComponentLight Chain, Heavy Chain, Fc Region, Antigen-Binding Site
ApplicationOncology, Autoimmune Diseases, Infectious Diseases, Cardiovascular Diseases, Neurological Disorders
End UserPharmaceutical Companies, Biotechnology Companies, Research Institutes, Contract Research Organizations
ProcessDiscovery, Development, Manufacturing, Quality Control, Regulatory Approval
DeploymentIn-house, Outsourced, Hybrid
FunctionalityTarget Binding, Immune Modulation, Signal Transduction
StagePreclinical, Clinical Trials, Marketed

Market Snapshot:

The Bispecific Antibodies Market is marked by a dynamic reshaping of market share, driven by innovative pricing strategies and the introduction of groundbreaking products. Companies are increasingly focusing on strategic launches to capture unmet medical needs, enhancing their competitive edge. The market landscape is characterized by a robust pipeline of products, with an emphasis on novel therapeutic areas. This strategic approach is fostering a competitive environment where pricing plays a pivotal role in market penetration and consumer adoption. Competition within the Bispecific Antibodies Market is intense, with leading pharmaceutical giants vying for dominance. Benchmarking reveals a landscape where regulatory frameworks significantly influence market trajectories. North America and Europe are at the forefront, with stringent regulatory standards shaping market dynamics. Asia-Pacific, however, is witnessing a surge in investment and regulatory easing, fostering a conducive environment for growth. The interplay of these factors presents a complex yet promising landscape for stakeholders looking to capitalize on emerging opportunities.

Geographical Overview:

The bispecific antibodies market is witnessing substantial growth across various regions, each presenting unique opportunities. North America leads the market, driven by advanced healthcare infrastructure and significant investments in biotechnology. The region's strong emphasis on research and development fosters innovation in bispecific antibody therapies. Europe follows closely, with robust regulatory frameworks and increased government funding supporting the market's expansion. The region's focus on personalized medicine enhances its market potential. In Asia Pacific, the market is expanding rapidly, fueled by rising healthcare expenditure and increasing prevalence of chronic diseases. Countries like China and India are emerging as key growth pockets, with substantial investments in biopharmaceutical research. Latin America and the Middle East & Africa are nascent markets with growing potential. Latin America benefits from improving healthcare infrastructure and increased access to innovative therapies, while the Middle East & Africa are focusing on advancing their biotechnology sectors to drive market growth and innovation.

Key Trends and Drivers:

The bispecific antibodies market is experiencing robust growth driven by advancements in biotechnology and increasing cancer prevalence. These antibodies offer targeted therapies, enhancing treatment efficacy and reducing side effects, which is propelling their adoption. Key trends include the development of novel bispecific constructs, improving specificity and functionality, and expanding therapeutic applications beyond oncology. Pharmaceutical companies are investing heavily in research and development to create innovative bispecific platforms. This investment is accelerating product pipelines and facilitating faster regulatory approvals. The market is also witnessing strategic collaborations and partnerships, enhancing technological capabilities and expanding market reach. Additionally, the increasing focus on personalized medicine is creating opportunities for bispecific antibodies to address unmet medical needs. Emerging markets are showing significant potential due to rising healthcare expenditure and improving infrastructure. There is a growing demand for advanced biologics, providing lucrative opportunities for market players. As awareness of bispecific antibodies increases, the market is poised for sustained growth, driven by technological advancements and strategic industry alliances.

Restraints and Challenges:

The bispecific antibodies market encounters several significant restraints and challenges. A primary challenge is the intricate manufacturing process, which demands specialized facilities and expertise, thus inflating production costs. This complexity can hinder scalability and limit the ability to meet growing demand. Regulatory hurdles also present a formidable challenge. The stringent approval processes for bispecific antibodies can delay market entry and increase development costs. Companies must navigate a complex landscape of regulations that vary by region, complicating international expansion. The market also faces substantial competition from conventional monoclonal antibodies and other emerging therapies. These alternatives often have established efficacy and safety profiles, making it difficult for bispecific antibodies to gain a foothold. Moreover, there is a shortage of skilled professionals equipped to develop and manage bispecific antibody therapies. This talent gap can slow innovation and impede progress in the field. Lastly, reimbursement issues pose a significant barrier. The high costs associated with bispecific antibodies can lead to challenges in securing coverage from insurance providers, limiting patient access and market growth.

Key Players:

Genmab, MacroGenics, Crescendo Biologics, F-star Therapeutics, Xencor, Zymeworks, Affimed, Harpoon Therapeutics, Immunocore, AbCellera, Regeneron Pharmaceuticals, Pieris Pharmaceuticals, Adimab, Ichnos Sciences, Sorrento Therapeutics

Research Scope:

  • Estimates and forecasts the overall market size across type, application, and region.
  • Provides detailed information and key takeaways on qualitative and quantitative trends, dynamics, business framework, competitive landscape, and company profiling.
  • Identifies factors influencing market growth and challenges, opportunities, drivers, and restraints.
  • Identifies factors that could limit company participation in international markets to help calibrate market share expectations and growth rates.
  • Evaluates key development strategies like acquisitions, product launches, mergers, collaborations, business expansions, agreements, partnerships, and R&D activities.
  • Analyzes smaller market segments strategically, focusing on their potential, growth patterns, and impact on the overall market.
  • Outlines the competitive landscape, assessing business and corporate strategies to monitor and dissect competitive advancements.

Our research scope provides comprehensive market data, insights, and analysis across a variety of critical areas. We cover Local Market Analysis, assessing consumer demographics, purchasing behaviors, and market size within specific regions to identify growth opportunities. Our Local Competition Review offers a detailed evaluation of competitors, including their strengths, weaknesses, and market positioning. We also conduct Local Regulatory Reviews to ensure businesses comply with relevant laws and regulations. Industry Analysis provides an in-depth look at market dynamics, key players, and trends. Additionally, we offer Cross-Segmental Analysis to identify synergies between different market segments, as well as Production-Consumption and Demand-Supply Analysis to optimize supply chain efficiency. Our Import-Export Analysis helps businesses navigate global trade environments by evaluating trade flows and policies. These insights empower clients to make informed strategic decisions, mitigate risks, and capitalize on market opportunities.

TABLE OF CONTENTS

1 Executive Summary

  • 1.1 Market Size and Forecast
  • 1.2 Market Overview
  • 1.3 Market Snapshot
  • 1.4 Regional Snapshot
  • 1.5 Strategic Recommendations
  • 1.6 Analyst Notes

2 Market Highlights

  • 2.1 Key Market Highlights by Type
  • 2.2 Key Market Highlights by Product
  • 2.3 Key Market Highlights by Technology
  • 2.4 Key Market Highlights by Component
  • 2.5 Key Market Highlights by Application
  • 2.6 Key Market Highlights by End User
  • 2.7 Key Market Highlights by Process
  • 2.8 Key Market Highlights by Deployment
  • 2.9 Key Market Highlights by Functionality
  • 2.10 Key Market Highlights by Stage

3 Market Dynamics

  • 3.1 Macroeconomic Analysis
  • 3.2 Market Trends
  • 3.3 Market Drivers
  • 3.4 Market Opportunities
  • 3.5 Market Restraints
  • 3.6 CAGR Growth Analysis
  • 3.7 Impact Analysis
  • 3.8 Emerging Markets
  • 3.9 Technology Roadmap
  • 3.10 Strategic Frameworks
    • 3.10.1 PORTER's 5 Forces Model
    • 3.10.2 ANSOFF Matrix
    • 3.10.3 4P's Model
    • 3.10.4 PESTEL Analysis

4 Segment Analysis

  • 4.1 Market Size & Forecast by Type (2020-2035)
    • 4.1.1 T-cell Engagers
    • 4.1.2 NK-cell Engagers
    • 4.1.3 Antibody-Drug Conjugates
    • 4.1.4 Dual-Affinity Re-Targeting Antibodies
    • 4.1.5 Bifunctional Antibodies
    • 4.1.6 Trifunctional Antibodies
  • 4.2 Market Size & Forecast by Product (2020-2035)
    • 4.2.1 Therapeutic Antibodies
    • 4.2.2 Diagnostic Antibodies
    • 4.2.3 Research Antibodies
    • 4.2.4 Custom Antibodies
  • 4.3 Market Size & Forecast by Technology (2020-2035)
    • 4.3.1 Hybridoma Technology
    • 4.3.2 Phage Display Technology
    • 4.3.3 Transgenic Mouse Technology
    • 4.3.4 Single B Cell Technology
  • 4.4 Market Size & Forecast by Component (2020-2035)
    • 4.4.1 Light Chain
    • 4.4.2 Heavy Chain
    • 4.4.3 Fc Region
    • 4.4.4 Antigen-Binding Site
  • 4.5 Market Size & Forecast by Application (2020-2035)
    • 4.5.1 Oncology
    • 4.5.2 Autoimmune Diseases
    • 4.5.3 Infectious Diseases
    • 4.5.4 Cardiovascular Diseases
    • 4.5.5 Neurological Disorders
  • 4.6 Market Size & Forecast by End User (2020-2035)
    • 4.6.1 Pharmaceutical Companies
    • 4.6.2 Biotechnology Companies
    • 4.6.3 Research Institutes
    • 4.6.4 Contract Research Organizations
  • 4.7 Market Size & Forecast by Process (2020-2035)
    • 4.7.1 Discovery
    • 4.7.2 Development
    • 4.7.3 Manufacturing
    • 4.7.4 Quality Control
    • 4.7.5 Regulatory Approval
  • 4.8 Market Size & Forecast by Deployment (2020-2035)
    • 4.8.1 In-house
    • 4.8.2 Outsourced
    • 4.8.3 Hybrid
  • 4.9 Market Size & Forecast by Functionality (2020-2035)
    • 4.9.1 Target Binding
    • 4.9.2 Immune Modulation
    • 4.9.3 Signal Transduction
  • 4.10 Market Size & Forecast by Stage (2020-2035)
    • 4.10.1 Preclinical
    • 4.10.2 Clinical Trials
    • 4.10.3 Marketed

5 Regional Analysis

  • 5.1 Global Market Overview
  • 5.2 North America Market Size (2020-2035)
    • 5.2.1 United States
      • 5.2.1.1 Type
      • 5.2.1.2 Product
      • 5.2.1.3 Technology
      • 5.2.1.4 Component
      • 5.2.1.5 Application
      • 5.2.1.6 End User
      • 5.2.1.7 Process
      • 5.2.1.8 Deployment
      • 5.2.1.9 Functionality
      • 5.2.1.10 Stage
    • 5.2.2 Canada
      • 5.2.2.1 Type
      • 5.2.2.2 Product
      • 5.2.2.3 Technology
      • 5.2.2.4 Component
      • 5.2.2.5 Application
      • 5.2.2.6 End User
      • 5.2.2.7 Process
      • 5.2.2.8 Deployment
      • 5.2.2.9 Functionality
      • 5.2.2.10 Stage
    • 5.2.3 Mexico
      • 5.2.3.1 Type
      • 5.2.3.2 Product
      • 5.2.3.3 Technology
      • 5.2.3.4 Component
      • 5.2.3.5 Application
      • 5.2.3.6 End User
      • 5.2.3.7 Process
      • 5.2.3.8 Deployment
      • 5.2.3.9 Functionality
      • 5.2.3.10 Stage
  • 5.3 Latin America Market Size (2020-2035)
    • 5.3.1 Brazil
      • 5.3.1.1 Type
      • 5.3.1.2 Product
      • 5.3.1.3 Technology
      • 5.3.1.4 Component
      • 5.3.1.5 Application
      • 5.3.1.6 End User
      • 5.3.1.7 Process
      • 5.3.1.8 Deployment
      • 5.3.1.9 Functionality
      • 5.3.1.10 Stage
    • 5.3.2 Argentina
      • 5.3.2.1 Type
      • 5.3.2.2 Product
      • 5.3.2.3 Technology
      • 5.3.2.4 Component
      • 5.3.2.5 Application
      • 5.3.2.6 End User
      • 5.3.2.7 Process
      • 5.3.2.8 Deployment
      • 5.3.2.9 Functionality
      • 5.3.2.10 Stage
    • 5.3.3 Rest of Latin America
      • 5.3.3.1 Type
      • 5.3.3.2 Product
      • 5.3.3.3 Technology
      • 5.3.3.4 Component
      • 5.3.3.5 Application
      • 5.3.3.6 End User
      • 5.3.3.7 Process
      • 5.3.3.8 Deployment
      • 5.3.3.9 Functionality
      • 5.3.3.10 Stage
  • 5.4 Asia-Pacific Market Size (2020-2035)
    • 5.4.1 China
      • 5.4.1.1 Type
      • 5.4.1.2 Product
      • 5.4.1.3 Technology
      • 5.4.1.4 Component
      • 5.4.1.5 Application
      • 5.4.1.6 End User
      • 5.4.1.7 Process
      • 5.4.1.8 Deployment
      • 5.4.1.9 Functionality
      • 5.4.1.10 Stage
    • 5.4.2 India
      • 5.4.2.1 Type
      • 5.4.2.2 Product
      • 5.4.2.3 Technology
      • 5.4.2.4 Component
      • 5.4.2.5 Application
      • 5.4.2.6 End User
      • 5.4.2.7 Process
      • 5.4.2.8 Deployment
      • 5.4.2.9 Functionality
      • 5.4.2.10 Stage
    • 5.4.3 South Korea
      • 5.4.3.1 Type
      • 5.4.3.2 Product
      • 5.4.3.3 Technology
      • 5.4.3.4 Component
      • 5.4.3.5 Application
      • 5.4.3.6 End User
      • 5.4.3.7 Process
      • 5.4.3.8 Deployment
      • 5.4.3.9 Functionality
      • 5.4.3.10 Stage
    • 5.4.4 Japan
      • 5.4.4.1 Type
      • 5.4.4.2 Product
      • 5.4.4.3 Technology
      • 5.4.4.4 Component
      • 5.4.4.5 Application
      • 5.4.4.6 End User
      • 5.4.4.7 Process
      • 5.4.4.8 Deployment
      • 5.4.4.9 Functionality
      • 5.4.4.10 Stage
    • 5.4.5 Australia
      • 5.4.5.1 Type
      • 5.4.5.2 Product
      • 5.4.5.3 Technology
      • 5.4.5.4 Component
      • 5.4.5.5 Application
      • 5.4.5.6 End User
      • 5.4.5.7 Process
      • 5.4.5.8 Deployment
      • 5.4.5.9 Functionality
      • 5.4.5.10 Stage
    • 5.4.6 Taiwan
      • 5.4.6.1 Type
      • 5.4.6.2 Product
      • 5.4.6.3 Technology
      • 5.4.6.4 Component
      • 5.4.6.5 Application
      • 5.4.6.6 End User
      • 5.4.6.7 Process
      • 5.4.6.8 Deployment
      • 5.4.6.9 Functionality
      • 5.4.6.10 Stage
    • 5.4.7 Rest of APAC
      • 5.4.7.1 Type
      • 5.4.7.2 Product
      • 5.4.7.3 Technology
      • 5.4.7.4 Component
      • 5.4.7.5 Application
      • 5.4.7.6 End User
      • 5.4.7.7 Process
      • 5.4.7.8 Deployment
      • 5.4.7.9 Functionality
      • 5.4.7.10 Stage
  • 5.5 Europe Market Size (2020-2035)
    • 5.5.1 Germany
      • 5.5.1.1 Type
      • 5.5.1.2 Product
      • 5.5.1.3 Technology
      • 5.5.1.4 Component
      • 5.5.1.5 Application
      • 5.5.1.6 End User
      • 5.5.1.7 Process
      • 5.5.1.8 Deployment
      • 5.5.1.9 Functionality
      • 5.5.1.10 Stage
    • 5.5.2 France
      • 5.5.2.1 Type
      • 5.5.2.2 Product
      • 5.5.2.3 Technology
      • 5.5.2.4 Component
      • 5.5.2.5 Application
      • 5.5.2.6 End User
      • 5.5.2.7 Process
      • 5.5.2.8 Deployment
      • 5.5.2.9 Functionality
      • 5.5.2.10 Stage
    • 5.5.3 United Kingdom
      • 5.5.3.1 Type
      • 5.5.3.2 Product
      • 5.5.3.3 Technology
      • 5.5.3.4 Component
      • 5.5.3.5 Application
      • 5.5.3.6 End User
      • 5.5.3.7 Process
      • 5.5.3.8 Deployment
      • 5.5.3.9 Functionality
      • 5.5.3.10 Stage
    • 5.5.4 Spain
      • 5.5.4.1 Type
      • 5.5.4.2 Product
      • 5.5.4.3 Technology
      • 5.5.4.4 Component
      • 5.5.4.5 Application
      • 5.5.4.6 End User
      • 5.5.4.7 Process
      • 5.5.4.8 Deployment
      • 5.5.4.9 Functionality
      • 5.5.4.10 Stage
    • 5.5.5 Italy
      • 5.5.5.1 Type
      • 5.5.5.2 Product
      • 5.5.5.3 Technology
      • 5.5.5.4 Component
      • 5.5.5.5 Application
      • 5.5.5.6 End User
      • 5.5.5.7 Process
      • 5.5.5.8 Deployment
      • 5.5.5.9 Functionality
      • 5.5.5.10 Stage
    • 5.5.6 Rest of Europe
      • 5.5.6.1 Type
      • 5.5.6.2 Product
      • 5.5.6.3 Technology
      • 5.5.6.4 Component
      • 5.5.6.5 Application
      • 5.5.6.6 End User
      • 5.5.6.7 Process
      • 5.5.6.8 Deployment
      • 5.5.6.9 Functionality
      • 5.5.6.10 Stage
  • 5.6 Middle East & Africa Market Size (2020-2035)
    • 5.6.1 Saudi Arabia
      • 5.6.1.1 Type
      • 5.6.1.2 Product
      • 5.6.1.3 Technology
      • 5.6.1.4 Component
      • 5.6.1.5 Application
      • 5.6.1.6 End User
      • 5.6.1.7 Process
      • 5.6.1.8 Deployment
      • 5.6.1.9 Functionality
      • 5.6.1.10 Stage
    • 5.6.2 United Arab Emirates
      • 5.6.2.1 Type
      • 5.6.2.2 Product
      • 5.6.2.3 Technology
      • 5.6.2.4 Component
      • 5.6.2.5 Application
      • 5.6.2.6 End User
      • 5.6.2.7 Process
      • 5.6.2.8 Deployment
      • 5.6.2.9 Functionality
      • 5.6.2.10 Stage
    • 5.6.3 South Africa
      • 5.6.3.1 Type
      • 5.6.3.2 Product
      • 5.6.3.3 Technology
      • 5.6.3.4 Component
      • 5.6.3.5 Application
      • 5.6.3.6 End User
      • 5.6.3.7 Process
      • 5.6.3.8 Deployment
      • 5.6.3.9 Functionality
      • 5.6.3.10 Stage
    • 5.6.4 Sub-Saharan Africa
      • 5.6.4.1 Type
      • 5.6.4.2 Product
      • 5.6.4.3 Technology
      • 5.6.4.4 Component
      • 5.6.4.5 Application
      • 5.6.4.6 End User
      • 5.6.4.7 Process
      • 5.6.4.8 Deployment
      • 5.6.4.9 Functionality
      • 5.6.4.10 Stage
    • 5.6.5 Rest of MEA
      • 5.6.5.1 Type
      • 5.6.5.2 Product
      • 5.6.5.3 Technology
      • 5.6.5.4 Component
      • 5.6.5.5 Application
      • 5.6.5.6 End User
      • 5.6.5.7 Process
      • 5.6.5.8 Deployment
      • 5.6.5.9 Functionality
      • 5.6.5.10 Stage

6 Market Strategy

  • 6.1 Demand-Supply Gap Analysis
  • 6.2 Trade & Logistics Constraints
  • 6.3 Price-Cost-Margin Trends
  • 6.4 Market Penetration
  • 6.5 Consumer Analysis
  • 6.6 Regulatory Snapshot

7 Competitive Intelligence

  • 7.1 Market Positioning
  • 7.2 Market Share
  • 7.3 Competition Benchmarking
  • 7.4 Top Company Strategies

8 Company Profiles

  • 8.1 Genmab
    • 8.1.1 Overview
    • 8.1.2 Product Summary
    • 8.1.3 Financial Performance
    • 8.1.4 SWOT Analysis
  • 8.2 MacroGenics
    • 8.2.1 Overview
    • 8.2.2 Product Summary
    • 8.2.3 Financial Performance
    • 8.2.4 SWOT Analysis
  • 8.3 Crescendo Biologics
    • 8.3.1 Overview
    • 8.3.2 Product Summary
    • 8.3.3 Financial Performance
    • 8.3.4 SWOT Analysis
  • 8.4 F-star Therapeutics
    • 8.4.1 Overview
    • 8.4.2 Product Summary
    • 8.4.3 Financial Performance
    • 8.4.4 SWOT Analysis
  • 8.5 Xencor
    • 8.5.1 Overview
    • 8.5.2 Product Summary
    • 8.5.3 Financial Performance
    • 8.5.4 SWOT Analysis
  • 8.6 Zymeworks
    • 8.6.1 Overview
    • 8.6.2 Product Summary
    • 8.6.3 Financial Performance
    • 8.6.4 SWOT Analysis
  • 8.7 Affimed
    • 8.7.1 Overview
    • 8.7.2 Product Summary
    • 8.7.3 Financial Performance
    • 8.7.4 SWOT Analysis
  • 8.8 Harpoon Therapeutics
    • 8.8.1 Overview
    • 8.8.2 Product Summary
    • 8.8.3 Financial Performance
    • 8.8.4 SWOT Analysis
  • 8.9 Immunocore
    • 8.9.1 Overview
    • 8.9.2 Product Summary
    • 8.9.3 Financial Performance
    • 8.9.4 SWOT Analysis
  • 8.10 AbCellera
    • 8.10.1 Overview
    • 8.10.2 Product Summary
    • 8.10.3 Financial Performance
    • 8.10.4 SWOT Analysis
  • 8.11 Regeneron Pharmaceuticals
    • 8.11.1 Overview
    • 8.11.2 Product Summary
    • 8.11.3 Financial Performance
    • 8.11.4 SWOT Analysis
  • 8.12 Pieris Pharmaceuticals
    • 8.12.1 Overview
    • 8.12.2 Product Summary
    • 8.12.3 Financial Performance
    • 8.12.4 SWOT Analysis
  • 8.13 Adimab
    • 8.13.1 Overview
    • 8.13.2 Product Summary
    • 8.13.3 Financial Performance
    • 8.13.4 SWOT Analysis
  • 8.14 Ichnos Sciences
    • 8.14.1 Overview
    • 8.14.2 Product Summary
    • 8.14.3 Financial Performance
    • 8.14.4 SWOT Analysis
  • 8.15 Sorrento Therapeutics
    • 8.15.1 Overview
    • 8.15.2 Product Summary
    • 8.15.3 Financial Performance
    • 8.15.4 SWOT Analysis

9 About Us

  • 9.1 About Us
  • 9.2 Research Methodology
  • 9.3 Research Workflow
  • 9.4 Consulting Services
  • 9.5 Our Clients
  • 9.6 Client Testimonials
  • 9.7 Contact Us